Winsights names scientific advisors and launches HSP study

Winsights on July 14, 2026, named a multidisciplinary advisory group and launched its first observational study focused on hereditary spastic paraplegia, including AP-4-HSP (SPG47). The Boston-based patient data platform says the effort is designed to turn lived experience into real-world evidence that can support rare disease research, clinical trial readiness and therapeutic development.

Why it matters: - Rare disease research often lacks enough patient-reported data to show how a condition affects daily life. - Winsights is trying to close that gap by collecting structured input from patients and caregivers. - The company says that evidence can help researchers understand disease burden, shape future studies, improve clinical trial readiness and support therapeutic development.

What happened: - Winsights announced a group of scientific and clinical advisors on July 14, 2026. - The company also launched its first observational research initiative focused on hereditary spastic paraplegia, including AP-4-HSP (SPG47). - The initiative debuts in Boston, where Winsights is based. - The advisory group includes experts from Harvard Medical School, the University of Michigan, Cornell Tech, Texas A&M and former FDA leadership.

The details: - The inaugural advisory group includes Saurabh Biswas of Texas A&M University and Texas A&M Engineering. - Craig Blackstone serves as Julieanne Dorn Professor of Neurology at Harvard Medical School and scientific director of the Mass General Brigham Neuroscience Institute. - Jessica Duis is a board-certified geneticist and rare disease physician, and she is leading the observational research initiative. - John K. Fink directs the Neurogenetic Disorders Clinic at the University of Michigan and is an expert in hereditary spastic paraplegia and neurogenetic disorders. - Thomas Kent is a neurology physician-scientist at Texas A&M Health Science Center-Houston and director of the Gulf Coast Consortium Rare Disease Network. - Tamar Lasky is a former senior advisor on real-world evidence at the U.S. Food and Drug Administration. - Thijs Roumen is an assistant professor of information science at Cornell Tech. - Richard Novak is the founding CEO of Unravel Biosciences and a former lead engineer at the Harvard Wyss Institute. - The HSP study will examine disease burden, symptom progression, quality of life and caregiver experiences. - AP-4-HSP was selected because it reflects the community that inspired Winsights and offers a test case for patient-generated insights in rare disease research. - Winsights was founded by rare disease advocate Kasey Walsh, who is a caregiver and mother of a daughter with a rare genetic disorder. - The company says it was created to address delayed diagnoses, limited natural history data and gaps in understanding daily disease impact. - Winsights plans to expand into additional rare disease communities and work with advocacy organizations, clinicians, researchers and industry. - More information is available in the company's announcement.

Between the lines: - The advisory board mixes clinical, regulatory, research, engineering and patient-centered expertise. - That mix suggests Winsights wants to position patient experience data as a credible evidence source for both science and industry. - The launch also gives Winsights a defined first disease area, which can help prove whether the model works before broader expansion.

What's next: - Winsights will use the advisory group to guide evidence generation, community engagement and future research initiatives. - The company plans to broaden its work into more rare disease communities. - The HSP study is likely to produce the first data set Winsights can use to show how its platform performs in practice.

The bottom line: - Winsights is betting that patient and caregiver experience can fill a major evidence gap in rare disease research, starting with hereditary spastic paraplegia.